Compare Heron Therapeutics Inc (HRTX) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Kohl's Corporation — how do they compare? Heron Therapeutics Inc trades at $0.33 (market cap $61.47M), while Kohl's Corporation trades at $18.73 (market cap $2.10B). The key difference: Kohl's Corporation is far larger — about 34.2× Heron Therapeutics Inc's market cap, and Kohl's Corporation pays a 2.7% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | KSS | |
|---|---|---|
Market Cap | $61.47M | $2.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $24.71 |
52-Week Low | $0.32 | $11.72 |
Enterprise Value | $168.21M | $8.20B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
Kohl's stock trades at $19.04, down 1.35% with a bullish technical signal despite recent weakness. The company shows improving fundamentals with three consecutive earnings beats and positive cash flow projections for 2026. Valuation metrics appear attractive with P/E of 7.77 and P/B of 0.52, while recent management changes and proprietary brand growth provide operational momentum.
Kohl's presents a turnaround opportunity with undervalued metrics and improving operational execution, though declining revenue and thin margins pose significant challenges. Analyst consensus remains cautious with a $16.75 price target below current levels, reflecting concerns about sustained growth in a competitive retail environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
